Microglia in Cancer Therapy-Related Cognitive Impairment
Trends in Neurosciences, ISSN: 0166-2236, Vol: 44, Issue: 6, Page: 441-451
2021
- 63Citations
- 135Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations63
- Citation Indexes63
- 63
- CrossRef25
- Captures135
- Readers135
- 135
- Mentions2
- Blog Mentions1
- 1
- News Mentions1
- 1
Most Recent Blog
Clearing the fog around brain fog
When was the last time you forgot where you kept your keys, or blanked out on someone’s name during an important conversation, or got distracted and abandoned an important task? While everyone might have faced these problems on more than one occasion, chances are that for most of us, these events are few and far […]
Most Recent News
Brain Fog Caused by Long COVID and Chemo Appear Similar
Data from mouse models for mild coronavirus infections and human tissue samples offer further evidence that it doesn’t take a severe infection—or even infection of brain cells at all—to cause long-term neurological symptoms.
Review Description
Millions of cancer survivors experience a persistent neurological syndrome that includes deficits in memory, attention, information processing, and mental health. Cancer therapy-related cognitive impairment can cause mild to severe disruptions to quality of life for these cancer survivors. Understanding the cellular and molecular underpinnings of this disorder will facilitate new therapeutic strategies aimed at ameliorating these long-lasting impairments. Accumulating evidence suggests that a range of cancer therapies induce persistent activation of the brain’s resident immune cells, microglia. Cancer therapy-induced microglial activation disrupts numerous mechanisms of neuroplasticity, and emerging findings suggest that this impairment in plasticity is central to cancer therapy-related cognitive impairment. This review explores reactive microglial dysregulation of neural circuit structure and function following cancer therapy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0166223621000357; http://dx.doi.org/10.1016/j.tins.2021.02.003; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85101887512&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33674135; https://linkinghub.elsevier.com/retrieve/pii/S0166223621000357; https://dx.doi.org/10.1016/j.tins.2021.02.003
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know